Stay updated on ORACLE: Liquid Biopsy in Residual Cancer Clinical Trial

Sign up to get notified when there's something new on the ORACLE: Liquid Biopsy in Residual Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ORACLE: Liquid Biopsy in Residual Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:41:08.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 on the webpage has recently changed to 8, indicating a potential update or revision in the data related to the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors in the ORACLE study.
    Difference
    0.1%
    Check dated 2024-06-06T14:42:57.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying age, treatment history, and follow-up requirements. Previously, this section indicated that no information was provided.
    Difference
    39%
    Check dated 2024-05-22T21:37:55.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:43:24.000Z thumbnail image

Stay in the know with updates to ORACLE: Liquid Biopsy in Residual Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ORACLE: Liquid Biopsy in Residual Cancer Clinical Trial page.